Evidence map›Paper›PMID 37853459›Full record

ArticleJournal of translational medicine2023

RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer.

Marzia Di Donato, Erika Di Zazzo, Annamaria Salvati, Carmela Sorrentino, Giorgio Giurato, Donatella Fiore, Maria Chiara Proto, Monica Rienzo, Amelia Casamassimi, Patrizia Gazzerro and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. PRDM Proteins Orchestrate Colorectal Cancer Tumorigenesis.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Marzia Di Donato *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Erika Di Zazzo *Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.
Annamaria Salvati *Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081, Baronissi, Italy.
Carmela SorrentinoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giorgio GiuratoLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081, Baronissi, Italy.
Donatella FioreDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Maria Chiara ProtoDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Monica RienzoDepartment of Environmental, Biological, and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy.
Amelia CasamassimiDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. amelia.casamassimi@unicampania.it.ORCID http://orcid.org/0000-0002-6010-4261
Patrizia GazzerroDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Maurizio BifulcoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
Gabriella CastoriaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Alessandro WeiszLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081, Baronissi, Italy.
Giovanni NassaLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081, Baronissi, Italy.
Ciro AbbondanzaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. ciro.abbondanza@unicampania.it.
University of Salerno · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Molise · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is the third most deadly and fourth most diagnosed cancer worldwide. Despite the progress in early diagnosis and advanced therapeutic options, CRC shows a poor prognosis with a 5 year survival rate of ~ 45%. PRDM2/RIZ, a member of PR/SET domain family (PRDM), expresses two main molecular variants, the PR-plus isoform (RIZ1) and the PR-minus (RIZ2). The imbalance in their expression levels in favor of RIZ2 is observed in many cancer types. The full length RIZ1 has been extensively investigated in several cancers where it acts as a tumor suppressor, whereas few studies have explored the RIZ2 oncogenic properties. PRDM2 is often target of frameshift mutations and aberrant DNA methylation in CRC. However, little is known about its role in CRC.

methodsWe combined in-silico investigation of The Cancer Genome Atlas (TCGA) CRC datasets, cellular and molecular assays, transcriptome sequencing and functional annotation analysis to assess the role of RIZ2 in human CRC.

resultsOur in-silico analysis on TCGA datasets confirmed that PRDM2 gene is frequently mutated and transcriptionally deregulated in CRC and revealed that a RIZ2 increase is highly correlated with a significant RIZ1 downregulation. Then, we assayed several CRC cell lines by qRT-PCR analysis for the main PRDM2 transcripts and selected DLD1 cell line, which showed the lowest RIZ2 levels. Therefore, we overexpressed RIZ2 in these cells to mimic TCGA datasets analysis results and consequently to assess the PRDM2/RIZ2 role in CRC. Data from RNA-seq disclosed that RIZ2 overexpression induced profound changes in CRC cell transcriptome via EGF pathway deregulation, suggesting that RIZ2 is involved in the EGF autocrine regulation of DLD1 cell behavior. Noteworthy, the forced RIZ2 expression increased cell viability, growth, colony formation, migration and organoid formation. These effects could be mediated by the release of high EGF levels by RIZ2 overexpressing DLD1 cells.

conclusionsOur findings add novel insights on the putative RIZ2 tumor-promoting functions in CRC, although additional efforts are warranted to define the underlying molecular mechanism.

Indexed as

Colorectal NeoplasmsEpidermal Growth FactorCell Line, TumorDNA-Binding ProteinsErbB ReceptorsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHistone-Lysine N-MethyltransferaseHumansNuclear ProteinsTranscription FactorsTumor Cells, CulturedDNA-Binding ProteinsEGFR protein, humanEpidermal Growth FactorErbB ReceptorsHistone-Lysine N-MethyltransferaseNuclear ProteinsPRDM2 protein, humanTranscription FactorsColorectal cancerEGFR pathwayPRDM2RIZ2 overexpressionRNA-seqZD1839

Identifiers

PMID37853459
PMCPMC10585774
OpenAlexW4387739287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.